Exelixis, Inc. (EXEL)
USD 34.69
(-5.44%)
USD 34.69
(-5.44%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -73.05 Million USD | 76.51% |
| 2022 | -311.02 Million USD | 47.81% |
| 2021 | -595.89 Million USD | -120.6% |
| 2020 | -270.13 Million USD | -25.2% |
| 2019 | -215.76 Million USD | 28.7% |
| 2018 | -302.59 Million USD | -79.44% |
| 2017 | -168.63 Million USD | -550.46% |
| 2016 | 37.43 Million USD | -84.39% |
| 2015 | 239.8 Million USD | -14.74% |
| 2014 | 281.26 Million USD | 15.62% |
| 2013 | 243.25 Million USD | 46.84% |
| 2012 | 165.66 Million USD | 54.46% |
| 2011 | 107.25 Million USD | -3.39% |
| 2010 | 111.01 Million USD | 1646.43% |
| 2009 | -7.17 Million USD | 94.48% |
| 2008 | -130.01 Million USD | -832.5% |
| 2007 | -13.94 Million USD | -712.53% |
| 2006 | -1.71 Million USD | -103.28% |
| 2005 | 52.37 Million USD | -24.36% |
| 2004 | 69.25 Million USD | 9407.8% |
| 2003 | -744 Thousand USD | 92.97% |
| 2002 | -10.58 Million USD | -179.26% |
| 2001 | 13.35 Million USD | 390.29% |
| 2000 | -4.6 Million USD | -158.25% |
| 1999 | 7.9 Million USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -63.9 Million USD | -257.78% |
| 2024 Q1 | -58.09 Million USD | 20.47% |
| 2024 Q2 | 40.5 Million USD | 169.72% |
| 2023 Q3 | -206 Million USD | 23.64% |
| 2023 Q4 | -73.05 Million USD | 64.54% |
| 2023 Q2 | -269.78 Million USD | 23.71% |
| 2023 Q1 | -353.64 Million USD | -13.7% |
| 2023 FY | -73.05 Million USD | 76.51% |
| 2022 Q4 | -311.02 Million USD | 39.66% |
| 2022 FY | -311.02 Million USD | 47.81% |
| 2022 Q1 | -672.63 Million USD | -12.88% |
| 2022 Q2 | -465.98 Million USD | 30.72% |
| 2022 Q3 | -515.44 Million USD | -10.62% |
| 2021 Q1 | -317.37 Million USD | -17.49% |
| 2021 Q2 | -439.23 Million USD | -38.4% |
| 2021 FY | -595.89 Million USD | -120.6% |
| 2021 Q4 | -595.89 Million USD | -15.69% |
| 2021 Q3 | -515.07 Million USD | -17.26% |
| 2020 Q3 | -286.42 Million USD | 40.18% |
| 2020 Q4 | -270.13 Million USD | 5.69% |
| 2020 FY | -270.13 Million USD | -25.2% |
| 2020 Q1 | -309.45 Million USD | -43.43% |
| 2020 Q2 | -478.8 Million USD | -54.73% |
| 2019 Q2 | -347.24 Million USD | 1.9% |
| 2019 FY | -215.76 Million USD | 28.7% |
| 2019 Q1 | -353.97 Million USD | -16.98% |
| 2019 Q4 | -215.76 Million USD | 1.3% |
| 2019 Q3 | -218.61 Million USD | 37.04% |
| 2018 Q3 | -341 Million USD | -49.72% |
| 2018 FY | -302.59 Million USD | -79.44% |
| 2018 Q4 | -302.59 Million USD | 11.26% |
| 2018 Q2 | -227.76 Million USD | 1.97% |
| 2018 Q1 | -232.33 Million USD | -37.77% |
| 2017 Q3 | -149.35 Million USD | -10.46% |
| 2017 Q1 | -69.83 Million USD | -286.53% |
| 2017 FY | -168.63 Million USD | -550.46% |
| 2017 Q4 | -168.63 Million USD | -12.91% |
| 2017 Q2 | -135.21 Million USD | -93.63% |
| 2016 Q3 | 79.63 Million USD | -70.09% |
| 2016 Q4 | 37.43 Million USD | -52.99% |
| 2016 Q1 | 111.77 Million USD | -53.39% |
| 2016 Q2 | 266.22 Million USD | 138.18% |
| 2016 FY | 37.43 Million USD | -84.39% |
| 2015 Q3 | 232.24 Million USD | -24.91% |
| 2015 Q4 | 239.8 Million USD | 3.25% |
| 2015 Q1 | 283.44 Million USD | 0.78% |
| 2015 FY | 239.8 Million USD | -14.74% |
| 2015 Q2 | 309.27 Million USD | 9.11% |
| 2014 Q1 | 185.48 Million USD | -23.75% |
| 2014 FY | 281.26 Million USD | 15.62% |
| 2014 Q3 | 255.15 Million USD | 26.54% |
| 2014 Q4 | 281.26 Million USD | 10.23% |
| 2014 Q2 | 201.63 Million USD | 8.71% |
| 2013 Q3 | 249.57 Million USD | 22.12% |
| 2013 Q2 | 204.36 Million USD | 28.03% |
| 2013 Q1 | 159.62 Million USD | -3.65% |
| 2013 FY | 243.25 Million USD | 46.84% |
| 2013 Q4 | 243.25 Million USD | -2.53% |
| 2012 FY | 165.66 Million USD | 54.46% |
| 2012 Q1 | 111.59 Million USD | 4.05% |
| 2012 Q2 | 114.55 Million USD | 2.65% |
| 2012 Q3 | 26.48 Million USD | -76.88% |
| 2012 Q4 | 165.66 Million USD | 525.44% |
| 2011 FY | 107.25 Million USD | -3.39% |
| 2011 Q4 | 107.25 Million USD | -25.38% |
| 2011 Q3 | 143.74 Million USD | 6.39% |
| 2011 Q2 | 135.11 Million USD | 2160.12% |
| 2011 Q1 | 5.97 Million USD | -94.62% |
| 2010 FY | 111.01 Million USD | 1646.43% |
| 2010 Q3 | 139.56 Million USD | 76.8% |
| 2010 Q1 | 18.07 Million USD | 351.83% |
| 2010 Q4 | 111.01 Million USD | -20.46% |
| 2010 Q2 | 78.94 Million USD | 336.65% |
| 2009 Q4 | -7.17 Million USD | 88.81% |
| 2009 Q3 | -64.13 Million USD | -49.79% |
| 2009 FY | -7.17 Million USD | 94.48% |
| 2009 Q2 | -42.81 Million USD | 51.16% |
| 2009 Q1 | -87.67 Million USD | 32.57% |
| 2008 Q3 | 59.14 Million USD | 11.99% |
| 2008 Q4 | -130.01 Million USD | -319.82% |
| 2008 Q1 | -4 Million USD | 71.3% |
| 2008 FY | -130.01 Million USD | -832.5% |
| 2008 Q2 | 52.81 Million USD | 1419.77% |
| 2007 Q4 | -13.94 Million USD | 51.85% |
| 2007 Q1 | -24.68 Million USD | -1338.52% |
| 2007 Q3 | -28.95 Million USD | -397.49% |
| 2007 FY | -13.94 Million USD | -712.53% |
| 2007 Q2 | 9.73 Million USD | 139.43% |
| 2006 Q4 | -1.71 Million USD | -103.02% |
| 2006 FY | -1.71 Million USD | -103.28% |
| 2006 Q3 | 56.79 Million USD | 97.0% |
| 2006 Q2 | 28.82 Million USD | 249.94% |
| 2006 Q1 | 8.23 Million USD | -84.27% |
| 2005 Q1 | 81.63 Million USD | 17.88% |
| 2005 Q2 | 42.45 Million USD | -47.99% |
| 2005 Q4 | 52.37 Million USD | -4.24% |
| 2005 Q3 | 54.7 Million USD | 28.85% |
| 2005 FY | 52.37 Million USD | -24.36% |
| 2004 Q3 | 64.44 Million USD | -5.3% |
| 2004 Q4 | 69.25 Million USD | 7.45% |
| 2004 Q1 | 27.15 Million USD | 3749.46% |
| 2004 FY | 69.25 Million USD | 9407.8% |
| 2004 Q2 | 68.05 Million USD | 150.66% |
| 2003 Q4 | -744 Thousand USD | -103.04% |
| 2003 FY | -744 Thousand USD | 92.97% |
| 2003 Q1 | 608 Thousand USD | 105.74% |
| 2003 Q2 | 7.63 Million USD | 1156.25% |
| 2003 Q3 | 24.45 Million USD | 220.18% |
| 2002 Q4 | -10.58 Million USD | -151.63% |
| 2002 FY | -10.58 Million USD | -179.26% |
| 2002 Q1 | 27.59 Million USD | 106.53% |
| 2002 Q2 | 44.11 Million USD | 59.91% |
| 2002 Q3 | 20.5 Million USD | -53.52% |
| 2001 Q1 | -26.97 Million USD | -486.07% |
| 2001 FY | 13.35 Million USD | 390.29% |
| 2001 Q3 | 7.72 Million USD | 146.62% |
| 2001 Q4 | 13.35 Million USD | 72.95% |
| 2001 Q2 | 3.13 Million USD | 111.61% |
| 2000 Q3 | -29.24 Million USD | 25.44% |
| 2000 Q2 | -39.22 Million USD | -5147.62% |
| 2000 Q1 | 777 Thousand USD | 0.0% |
| 2000 Q4 | -4.6 Million USD | 84.26% |
| 2000 FY | -4.6 Million USD | -158.25% |
| 1999 FY | 7.9 Million USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | -30.586% |
| Alkermes plc | -166.73 Million USD | 56.189% |
| Agenus Inc. | 274.13 Million USD | 126.647% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 103.907% |
| Aptorum Group Limited | 1.35 Million USD | 5483.016% |
| Ardelyx, Inc. | 34.51 Million USD | 311.666% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 1806.776% |
| Bicycle Therapeutics plc | -481.46 Million USD | 84.828% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 302.002% |
| ChromaDex Corporation | -24.04 Million USD | -203.767% |
| Chimerix, Inc. | -25.51 Million USD | -186.28% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 1148.353% |
| Caribou Biosciences, Inc. | -23.67 Million USD | -208.527% |
| CRISPR Therapeutics AG | -150.84 Million USD | 51.573% |
| Precision BioSciences, Inc. | -85.41 Million USD | 14.471% |
| Dyadic International, Inc. | -6.37 Million USD | -1045.326% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | -358.482% |
| Fortress Biotech, Inc. | 7.66 Million USD | 1053.033% |
| Lantern Pharma Inc. | -21.7 Million USD | -236.585% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 33.914% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | -755.068% |
| Incyte Corporation | -3.17 Billion USD | 97.699% |
| IO Biotech, Inc. | -140.69 Million USD | 48.081% |
| Jaguar Health, Inc. | 29.39 Million USD | 348.545% |
| Novavax, Inc. | -298.29 Million USD | 75.511% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 1468.746% |
| Opthea Limited | 28.15 Million USD | 359.434% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | -335.106% |
| ContextLogic Inc. | -232 Million USD | 68.513% |
| MiMedx Group, Inc. | -33.9 Million USD | -115.48% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 816.528% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | -3052.747% |
| NextCure, Inc. | -6.47 Million USD | -1027.837% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | -44.651% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | -1045.164% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 700.579% |
| Vaxcyte, Inc. | -368.22 Million USD | 80.162% |
| PDS Biotechnology Corporation | -32.7 Million USD | -123.334% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 522.792% |
| Pharming Group N.V. | 109.8 Million USD | 166.528% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | -319.924% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 58.312% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | -294.442% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | -294.442% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -928.873% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | -1146.587% |
| Acelyrin, Inc. | -216.9 Million USD | 66.321% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | -1202.077% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | -4137.239% |
| Summit Therapeutics Inc. | 34.67 Million USD | 310.677% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | -973.791% |
| Senti Biosciences, Inc. | 1.74 Million USD | 4298.276% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 60.429% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 5.682% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | -1105.048% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 73319.136% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 11732.166% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 37.589% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 56.578% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 165.888% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | -861.69% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 43.422% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 1159.525% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 69.859% |
| Immix Biopharma, Inc. | -17.5 Million USD | -317.195% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 76.934% |
| MEI Pharma, Inc. | -3.7 Million USD | -1871.66% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 683.886% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 145.165% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 362.836% |
| Fortress Biotech, Inc. | 7.66 Million USD | 1053.033% |
| Precigen, Inc. | -481 Thousand USD | -15087.11% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 618.784% |
| AlloVir, Inc. | -62.69 Million USD | -16.522% |
| C4 Therapeutics, Inc. | -55.61 Million USD | -31.352% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 218.461% |
| ImmuCell Corporation | 10.99 Million USD | 764.661% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 52.61% |
| Onconetix, Inc. | 5.33 Million USD | 1470.175% |
| PureTech Health plc | -167.19 Million USD | 56.309% |
| VYNE Therapeutics Inc. | -30.46 Million USD | -139.823% |
| Elevation Oncology, Inc. | -19.11 Million USD | -282.101% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | -1388.083% |
| Seer, Inc. | -4.24 Million USD | -1622.877% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | -203.906% |
| Innoviva, Inc. | 255.56 Million USD | 128.584% |
| Aadi Bioscience, Inc. | -55.86 Million USD | -30.764% |
| ESSA Pharma Inc. | -33.62 Million USD | -117.271% |
| GlycoMimetics, Inc. | -40.98 Million USD | -78.238% |
| GT Biopharma, Inc. | -1.02 Million USD | -7054.75% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | -7.77% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 219.252% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 45.517% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | -427.208% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | -153.013% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -96868.168% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | -136.699% |
| Aptose Biosciences Inc. | -8.19 Million USD | -791.413% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | -2234.598% |
| Soligenix, Inc. | -4.95 Million USD | -1375.282% |
| Century Therapeutics, Inc. | 847 Thousand USD | 8724.557% |
| Kura Oncology, Inc. | -20.11 Million USD | -263.108% |
| TScan Therapeutics, Inc. | -40.92 Million USD | -78.493% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | -769.85% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 4110.002% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | -2184.955% |
| Autolus Therapeutics plc | -186.59 Million USD | 60.852% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | -48.162% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 73.513% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 313.173% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 144.443% |
| GRI Bio, Inc. | -1.79 Million USD | -3971.906% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | -713.199% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | -119.653% |
| IGM Biosciences, Inc. | -72.6 Million USD | -0.612% |
| INmune Bio, Inc. | -25.41 Million USD | -187.474% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 148.393% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | -44.199% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -349.556% |
| Entero Therapeutics, Inc. | -2.88 Million USD | -2432.127% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 292.161% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | -77.37% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 329.105% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 119.328% |
| Verastem, Inc. | -37.27 Million USD | -95.96% |
| Abeona Therapeutics Inc. | -9.07 Million USD | -705.136% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | -40.855% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | -382.656% |
| Histogen Inc. | -7.48 Million USD | -875.691% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | -238.088% |
| Surrozen, Inc. | -32.66 Million USD | -123.641% |
| Organovo Holdings, Inc. | -1.5 Million USD | -4747.379% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -1637.842% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 485.281% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 2892.431% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 1857.7% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | -771.599% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | -68.155% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | -401.137% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 76.94% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -10016.888% |
| Apollomics, Inc. | -27.39 Million USD | -166.654% |
| Amarin Corporation plc | -191.04 Million USD | 61.762% |
| Mesoblast Limited | 55.96 Million USD | 230.533% |
| Turnstone Biologics Corp. | -14.58 Million USD | -400.891% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | -188.827% |
| Synaptogenix, Inc. | -28.66 Million USD | -154.872% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -7704.487% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 249.902% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -8373.603% |
| Monopar Therapeutics Inc. | -7.26 Million USD | -905.356% |
| Better Therapeutics, Inc. | -860 Thousand USD | -8394.186% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | -204.21% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 69.735% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 10024.382% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | -882.101% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 5925.359% |
| Gritstone bio, Inc. | 39.49 Million USD | 284.984% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 13.14% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | -2675.308% |
| Avid Bioservices, Inc. | 169.72 Million USD | 143.039% |
| Insmed Incorporated | 721.62 Million USD | 110.123% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | -699.102% |
| MediWound Ltd. | -5.32 Million USD | -1272.604% |
| OmniAb, Inc. | 9.2 Million USD | 893.763% |
| Alector, Inc. | -35.63 Million USD | -104.984% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 184.971% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | -1382.346% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 651.779% |
| Zai Lab Limited | -775 Million USD | 90.574% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 121.45% |
| Aura Biosciences, Inc. | -21.52 Million USD | -239.373% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 11.433% |
| Immunic, Inc. | -45.34 Million USD | -61.116% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 62.192% |
| Veracyte, Inc. | -203.82 Million USD | 64.16% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 111.445% |
| FibroGen, Inc. | 56.76 Million USD | 228.684% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 920.326% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | -2483.936% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | -3428.392% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 101.591% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | -2086.471% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 55.984% |
| TG Therapeutics, Inc. | 17.86 Million USD | 508.969% |
| Galecto, Inc. | -21.21 Million USD | -244.316% |
| Calithera Biosciences, Inc. | -23.78 Million USD | -207.126% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 104.655% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | -198.504% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | -534.831% |
| XBiotech Inc. | -200.02 Million USD | 63.479% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 13.14% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 1713.295% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | -107.158% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 5.398% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 1383.606% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 57.134% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 20.919% |
| Vaxxinity, Inc. | 10.13 Million USD | 820.983% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 109.922% |
| Gain Therapeutics, Inc. | -10.76 Million USD | -578.427% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | -10.756% |
| NexImmune, Inc. | -3.13 Million USD | -2231.153% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | -2015.752% |
| Marker Therapeutics, Inc. | -15.11 Million USD | -383.408% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -169.557% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | -713.832% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -58539.374% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | -80.05% |
| Ainos, Inc. | 4.07 Million USD | 1891.351% |
| Pluri Inc. | 22.82 Million USD | 419.988% |
| Prothena Corporation plc | -608.34 Million USD | 87.992% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 38.487% |
| Celularity Inc. | 65.19 Million USD | 212.057% |
| Rallybio Corporation | -24.1 Million USD | -203.087% |
| Cue Biopharma, Inc. | -33.81 Million USD | -116.003% |
| MeiraGTx Holdings plc | -40.3 Million USD | -81.257% |
| Omeros Corporation | 331.17 Million USD | 122.058% |
| Humacyte, Inc. | -22.48 Million USD | -224.869% |
| Immunocore Holdings plc | -358.59 Million USD | 79.629% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | -197.253% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | -136.4% |
| Blueprint Medicines Corporation | 702.83 Million USD | 110.394% |
| CalciMedica, Inc. | -5.53 Million USD | -1220.976% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 61.189% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | -615.195% |
| Scholar Rock Holding Corporation | -40.03 Million USD | -82.456% |
| Sana Biotechnology, Inc. | -33.25 Million USD | -119.679% |
| Pulmatrix, Inc. | -10.41 Million USD | -601.258% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | -1122.185% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | -91.521% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 34.427% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | -21.864% |
| Cytokinetics, Incorporated | 642.37 Million USD | 111.372% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | -1154.508% |
| Nutriband Inc. | -251.65 Thousand USD | -28927.605% |
| Protara Therapeutics, Inc. | -34.11 Million USD | -114.104% |
| Vor Biopharma Inc. | 4.3 Million USD | 1798.837% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 98.79% |
| Evogene Ltd. | -19.63 Million USD | -272.059% |
| ProKidney Corp. | -56.23 Million USD | -29.899% |
| Applied Therapeutics, Inc. | -48.67 Million USD | -50.086% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | -690.825% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 105.356% |
| CorMedix Inc. | -43.05 Million USD | -69.677% |
| BioLineRx Ltd. | 7.33 Million USD | 1095.774% |
| Tango Therapeutics, Inc. | -27.46 Million USD | -165.975% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 258.298% |
| Atai Life Sciences N.V. | -28.55 Million USD | -155.795% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 3375.008% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | -220.17% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 511.897% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 2.696% |
| MediciNova, Inc. | -50.78 Million USD | -43.846% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 7.303% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -324638.831% |
| GeoVax Labs, Inc. | -6.45 Million USD | -1032.104% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 63.442% |
| Biomea Fusion, Inc. | -166.57 Million USD | 56.145% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 59.184% |
| Mereo BioPharma Group plc | -51.46 Million USD | -41.93% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 22.979% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 75.133% |
| Absci Corporation | -72.59 Million USD | -0.623% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 1699.869% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 68.84% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 22.461% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 23.665% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | -86.958% |
| Allakos Inc. | -24.97 Million USD | -192.492% |
| Imunon, Inc. | -4.21 Million USD | -1633.568% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | -395.523% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 46.049% |
| BioAtla, Inc. | -109.01 Million USD | 32.988% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 10024.382% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -7679.553% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 710.48% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | -244.527% |
| XOMA Corporation | -29 Million USD | -151.897% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | -341.123% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -710.226% |
| aTyr Pharma, Inc. | -7.44 Million USD | -880.669% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 41.389% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 64.907% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 10.674% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 21.251% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -8402.253% |
| Akari Therapeutics, Plc | -3.84 Million USD | -1799.87% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 4601.229% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 105.29% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -6048.291% |
| UroGen Pharma Ltd. | 4.39 Million USD | 1763.63% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 164.372% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 101611.909% |
| Orgenesis Inc. | 21.78 Million USD | 435.338% |
| Entera Bio Ltd. | -10.62 Million USD | -587.271% |
| GH Research PLC | -78.07 Million USD | 6.439% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | -227.755% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | -174.016% |
| Xencor, Inc. | 29.64 Million USD | 346.424% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | -3608.476% |
| Replimune Group, Inc. | 1.41 Million USD | 5273.513% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -29727.527% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 42.215% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -6048.291% |
| Portage Biotech Inc. | -4.98 Million USD | -1366.573% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -324638.831% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | -10.478% |
| OncoCyte Corporation | -6.56 Million USD | -1013.058% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 8240.065% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | -1503.506% |
| Purple Biotech Ltd. | -14.13 Million USD | -416.693% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | -207.501% |
| scPharmaceuticals Inc. | -6.54 Million USD | -1016.119% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | -337.63% |
| HilleVax, Inc. | -165.48 Million USD | 55.857% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | -2778.251% |
| Tharimmune, Inc. | -10.93 Million USD | -568.017% |
| Genprex, Inc. | -6.73 Million USD | -984.209% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 80.193% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 17.42% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | -5114.133% |
| Virios Therapeutics, Inc. | -3.31 Million USD | -2102.327% |
| OKYO Pharma Limited | -826.84 Thousand USD | -8734.756% |
| Savara Inc. | 153 Thousand USD | 47845.098% |
| Curis, Inc. | -23.88 Million USD | -205.815% |
| Daré Bioscience, Inc. | -5.15 Million USD | -1316.271% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -9313.514% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | -1076.707% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 6264.557% |
| BeiGene, Ltd. | -2.25 Billion USD | 96.758% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 692.049% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 87.989% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 60.638% |
| Erasca, Inc. | -37.21 Million USD | -96.287% |
| bluebird bio, Inc. | 108.57 Million USD | 167.283% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -5572.055% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 119.287% |
| DBV Technologies S.A. | -126.98 Million USD | 42.474% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -5572.055% |
| Moderna, Inc. | -2.9 Billion USD | 97.487% |
| Vincerx Pharma, Inc. | -10.35 Million USD | -605.661% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | -572.157% |
| Molecular Templates, Inc. | 707 Thousand USD | 10432.39% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | -132.858% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 121.076% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 10.982% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 20.364% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | -126.357% |
| Cogent Biosciences, Inc. | -34.37 Million USD | -112.503% |
| MacroGenics, Inc. | -66.98 Million USD | -9.054% |
| RenovoRx, Inc. | -1.17 Million USD | -6127.621% |
| Adicet Bio, Inc. | -138.78 Million USD | 47.365% |
| Prime Medicine, Inc. | -27.94 Million USD | -161.444% |
| Aditxt, Inc. | 18.12 Million USD | 503.126% |
| Adagene Inc. | -87.62 Million USD | 16.636% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -1653.721% |
| Quantum-Si incorporated | -118.55 Million USD | 38.384% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 302.888% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | -877.364% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | -50.591% |
| SciSparc Ltd. | -2.06 Million USD | -3437.53% |
| Vericel Corporation | 1.27 Million USD | 5820.439% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -509.171% |
| Minerva Neurosciences, Inc. | 41 Million USD | 278.152% |
| Generation Bio Co. | 31.44 Million USD | 332.288% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 58.344% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | -136.232% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 162.654% |
| Invivyd, Inc. | -198.47 Million USD | 63.195% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 19.076% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | -2946.685% |
| Spero Therapeutics, Inc. | -70.79 Million USD | -3.193% |
| Artelo Biosciences, Inc. | -6.82 Million USD | -970.33% |
| 2seventy bio, Inc. | 181.71 Million USD | 140.2% |
| ADMA Biologics, Inc. | 90.06 Million USD | 181.107% |
| Clene Inc. | 3.34 Million USD | 2287.126% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | -704.276% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | -239.594% |
| GeoVax Labs, Inc. | -6.45 Million USD | -1032.104% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 78.772% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | -180.965% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 141.116% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | -1685.38% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 1560.416% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | -1302.38% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 43.939% |
| Evaxion Biotech A/S | 5.28 Million USD | 1481.732% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 35.106% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 44.353% |
| Trevena, Inc. | 2.25 Million USD | 3335.164% |
| Surrozen, Inc. | -32.66 Million USD | -123.641% |
| Tyra Biosciences, Inc. | -51.51 Million USD | -41.817% |
| Cingulate Inc. | 3.08 Million USD | 2469.689% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | -2387.232% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 1116.419% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | -686.226% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 7.908% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 44.428% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 30.786% |
| Clearmind Medicine Inc. | -3.94 Million USD | -1752.821% |
| Kronos Bio, Inc. | -36.05 Million USD | -102.613% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 876.384% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 5109.852% |
| Viking Therapeutics, Inc. | -54.25 Million USD | -34.639% |
| Statera Biopharma, Inc. | 14.41 Million USD | 606.714% |
| ImmunityBio, Inc. | 618.22 Million USD | 111.816% |
| Korro Bio, Inc. | -132.94 Million USD | 45.052% |
| Kineta, Inc. | -4.54 Million USD | -1508.677% |
| BioVie Inc. | -17.73 Million USD | -311.959% |
| Codexis, Inc. | -43.27 Million USD | -68.82% |
| Celularity Inc. | 65.19 Million USD | 212.057% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | -2205.144% |
| Celcuity Inc. | 6.78 Million USD | 1176.876% |
| Virax Biolabs Group Limited | -3.36 Million USD | -2070.913% |
| Cibus, Inc. | -8.07 Million USD | -804.308% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | -1627.359% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 1698.468% |
| IN8bio, Inc. | -16.38 Million USD | -345.726% |
| Kodiak Sciences Inc. | -103.87 Million USD | 29.675% |
| Annexon, Inc. | -193.75 Million USD | 62.298% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 203016.667% |
| Assembly Biosciences, Inc. | -17.49 Million USD | -317.452% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | -1979.419% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 106.929% |
| Eyenovia, Inc. | 1.25 Million USD | 5903.598% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 371.511% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -2152.544% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | -119.719% |
| Arcellx, Inc. | -296.95 Million USD | 75.401% |
| Cardiff Oncology, Inc. | -19.5 Million USD | -274.5% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | -24.076% |
| Regulus Therapeutics Inc. | -20.72 Million USD | -252.439% |
| Moolec Science SA | 117.61 Thousand USD | 62208.897% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | -90.239% |
| Geron Corporation | 14.76 Million USD | 594.885% |
| LAVA Therapeutics N.V. | -37.91 Million USD | -92.653% |
| Royalty Pharma plc | 5.65 Billion USD | 101.291% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 48.346% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | -945.151% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | -1262.147% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 48.092% |
| Humacyte, Inc. | -22.48 Million USD | -224.869% |
| Structure Therapeutics Inc. | -124.33 Million USD | 41.249% |
| 89bio, Inc. | -289.05 Million USD | 74.728% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | -189.399% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | -3997.027% |
| Genelux Corporation | -6.89 Million USD | -958.849% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | -135.198% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 187.381% |
| Notable Labs, Ltd. | -9.77 Million USD | -647.238% |
| Liquidia Corporation | -80.17 Million USD | 8.888% |
| Mustang Bio, Inc. | -3.73 Million USD | -1855.3% |
| Immunovant, Inc. | -635.22 Million USD | 88.5% |
| Quantum-Si incorporated | -118.55 Million USD | 38.384% |
| Arbutus Biopharma Corporation | -17.56 Million USD | -315.908% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | -1663.215% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 1010.054% |
| Acasti Pharma Inc. | -23 Million USD | -217.54% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | -2069.44% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -349.556% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 46.965% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | -2244.079% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | -228.58% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | -293.398% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 56.846% |
| PepGen Inc. | -60.67 Million USD | -20.405% |
| Moleculin Biotech, Inc. | -22.97 Million USD | -217.94% |
| United Therapeutics Corporation | -507.7 Million USD | 85.612% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | -281.941% |
| Solid Biosciences Inc. | -47.75 Million USD | -52.984% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -8373.603% |
| Immuneering Corporation | -54.94 Million USD | -32.956% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -1637.842% |
| Silo Pharma, Inc. | -3.52 Million USD | -1972.747% |
| Belite Bio, Inc | -87.27 Million USD | 16.295% |
| XOMA Corporation | -29 Million USD | -151.897% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | -3.328% |
| Bionomics Limited | 227 Million USD | 132.179% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 37.179% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -2783.932% |
| uniQure N.V. | -102.95 Million USD | 29.044% |
| Cassava Sciences, Inc. | -121.13 Million USD | 39.696% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -1653.721% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 278.384% |
| Forte Biosciences, Inc. | -11.96 Million USD | -510.735% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | -2260.869% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 69015.094% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -2152.544% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 920.326% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | -885.032% |
| Altimmune, Inc. | -134.48 Million USD | 45.682% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 136.882% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -2783.932% |
| Compugen Ltd. | -12.9 Million USD | -466.104% |
| Peak Bio, Inc. | 10.34 Million USD | 806.469% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -25712.721% |
| Benitec Biopharma Inc. | -50.58 Million USD | -44.419% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 29.987% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 471.85% |
| Zura Bio Limited | -99.8 Million USD | 26.808% |
| PolyPid Ltd. | 6.17 Million USD | 1283.955% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 198.556% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 471.85% |
| Instil Bio, Inc. | 75.35 Million USD | 196.937% |
| argenx SE | -2.02 Billion USD | 96.399% |
| Immunome, Inc. | -97.02 Million USD | 24.713% |
| Compass Therapeutics, Inc. | -22.49 Million USD | -224.739% |
| Verona Pharma plc | -220.44 Million USD | 66.862% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | -1.822% |
| Shattuck Labs, Inc. | -121.42 Million USD | 39.839% |
| CervoMed Inc. | -7.79 Million USD | -837.398% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 60.62% |
| Plus Therapeutics, Inc. | -4.37 Million USD | -1570.478% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 44.55% |
| Moolec Science SA | 117.61 Thousand USD | 62208.897% |
| Enveric Biosciences, Inc. | -2.28 Million USD | -3092.777% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 559.481% |
| AnaptysBio, Inc. | -18.15 Million USD | -302.457% |
| Design Therapeutics, Inc. | -18.15 Million USD | -302.479% |
| Leap Therapeutics, Inc. | -70.38 Million USD | -3.792% |
| NeurAxis, Inc. | 145.7 Thousand USD | 50237.268% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 750.374% |
| Lumos Pharma, Inc. | -28.49 Million USD | -156.379% |
| Achilles Therapeutics plc | -126.92 Million USD | 42.446% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | -1.822% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -11040.256% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | -251.644% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 5109.852% |
| Nutriband Inc. | -251.65 Thousand USD | -28927.605% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | -454.628% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | -881.855% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 121.473% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 407.773% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 83.675% |
| Palisade Bio, Inc. | -12.06 Million USD | -505.571% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 47.937% |
| Beam Therapeutics Inc. | -262.72 Million USD | 72.195% |
| Neurogene Inc. | -131.95 Million USD | 44.64% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 434.846% |
| AEON Biopharma, Inc. | -4.88 Million USD | -1396.926% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 80.633% |
| Sesen Bio, Inc. | -112.55 Million USD | 35.097% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 26.848% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | -3011.433% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | -87.183% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 12.286% |
| Athira Pharma, Inc. | -88.99 Million USD | 17.92% |
| Vaccinex, Inc. | -1.28 Million USD | -5571.584% |
| HCW Biologics Inc. | 2.85 Million USD | 2657.168% |
| XOMA Corporation | -29 Million USD | -151.897% |
| Nektar Therapeutics | 210.24 Million USD | 134.746% |
| Arvinas, Inc. | -313.8 Million USD | 76.721% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 4601.229% |
| Merus N.V. | -192.88 Million USD | 62.127% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 221.78% |
| Quince Therapeutics, Inc. | -6.93 Million USD | -952.897% |
| Rezolute, Inc. | -68.16 Million USD | -7.162% |
| Clene Inc. | 3.34 Million USD | 2287.126% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | -453.955% |
| BeyondSpring Inc. | -13.75 Million USD | -431.08% |
| Synlogic, Inc. | -6.68 Million USD | -992.745% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 6541.799% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | -763.986% |
| Peak Bio, Inc. | 10.34 Million USD | 806.469% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 11.369% |
| Krystal Biotech, Inc. | -350.23 Million USD | 79.143% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 158.852% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 56.774% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | -2213.8% |
| MannKind Corporation | 143.89 Million USD | 150.765% |
| Ikena Oncology, Inc. | -109.15 Million USD | 33.077% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | -864.866% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | -120.695% |
| Gossamer Bio, Inc. | 180.35 Million USD | 140.503% |
| CohBar, Inc. | -5.93 Million USD | -1131.72% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | -145.563% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 1699.869% |
| Legend Biotech Corporation | -949.39 Million USD | 92.306% |
| Mural Oncology plc | -255.84 Million USD | 71.447% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 326.758% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | -1450.744% |
| Disc Medicine, Inc. | -358.28 Million USD | 79.611% |
| Champions Oncology, Inc. | 4.81 Million USD | 1618.08% |
| REGENXBIO Inc. | 54.76 Million USD | 233.381% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -27065.526% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 51.63% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | -710.585% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 9.46% |
| Vaxart, Inc. | -8.24 Million USD | -786.422% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | -45.576% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 42.555% |
| Cellectis S.A. | -43.85 Million USD | -66.572% |
| Longeveron Inc. | -2.9 Million USD | -2412.036% |
| Repare Therapeutics Inc. | -107.85 Million USD | 32.272% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 107.544% |
| Inozyme Pharma, Inc. | 12 Million USD | 708.547% |
| Revolution Medicines, Inc. | -608.2 Million USD | 87.989% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | -5839.024% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 72.446% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 51.323% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | -366.863% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -9771.622% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.236% |
| Denali Therapeutics Inc. | -74.86 Million USD | 2.424% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -509.171% |
| Veru Inc. | 4.77 Million USD | 1628.253% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | -549.564% |
| Cingulate Inc. | 3.08 Million USD | 2469.689% |
| Passage Bio, Inc. | 4.58 Million USD | 1693.239% |
| Context Therapeutics Inc. | -14.44 Million USD | -405.542% |
| Exicure, Inc. | 5.84 Million USD | 1348.931% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 68.291% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | -84.61% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 565.554% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | -24.19% |
| Nuvalent, Inc. | -335.38 Million USD | 78.219% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 4311.974% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 1.923% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | -721.71% |
| OmniAb, Inc. | 9.2 Million USD | 893.763% |
| Anew Medical, Inc. | 1.43 Million USD | 5199.601% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 545.923% |
| Lipocine Inc. | -4.75 Million USD | -1436.409% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 33.487% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 579.614% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | -44.199% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 393.468% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | -986.892% |
| Sage Therapeutics, Inc. | -65.82 Million USD | -10.973% |
| Ocugen, Inc. | -32.52 Million USD | -124.624% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 14.636% |
| Q32 Bio Inc. | -37.94 Million USD | -92.5% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -11532.166% |
| Alumis Inc. Common Stock | -13.52 Million USD | -439.951% |
| Equillium, Inc. | -22.39 Million USD | -226.233% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | -185.709% |
| Coya Therapeutics, Inc. | -32.62 Million USD | -123.896% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -29365.744% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 154.498% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 2384.24% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 22341.438% |
| Dominari Holdings Inc. | 195 Thousand USD | 37561.538% |
| Edesa Biotech, Inc. | -5.26 Million USD | -1286.961% |
| vTv Therapeutics Inc. | -8.91 Million USD | -719.222% |
| Bio-Techne Corporation | 267.74 Million USD | 127.283% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | -350.676% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 38.142% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | -769.332% |
| Candel Therapeutics, Inc. | -12.65 Million USD | -477.425% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 70.198% |
| Nkarta, Inc. | 57.29 Million USD | 227.489% |
| BioCardia, Inc. | 212 Thousand USD | 34557.547% |
| Iterum Therapeutics plc | 13.43 Million USD | 643.608% |